These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. Wong A; Riley M; Zhao S; Wang JG; Esguerra V; Li M; Lopez G; Otterson GA; Kendra K; Presley CJ; Wei L; Owen DH; Ho K Cancer Immunol Immunother; 2023 Jun; 72(6):1727-1735. PubMed ID: 36640189 [TBL] [Abstract][Full Text] [Related]
5. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350 [TBL] [Abstract][Full Text] [Related]
6. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer. Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100 [TBL] [Abstract][Full Text] [Related]
7. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review. Jayakrishnan B; Al-Moundhri M; Burney I; Al-Hashami Z; Al-Bimani K Adv Respir Med; 2022; 90(3):219-229. PubMed ID: 35731114 [TBL] [Abstract][Full Text] [Related]
9. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587 [TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Soto-Lanza F; Glick L; Chan C; Zhong L; Wilson N; Faiz S; Gandhi S; Naing A; Heymach JV; Shannon VR; Franco-Vega M; Liao Z; Lin SH; Palaskas NL; Wu J; Shroff GS; Altan M; Sheshadri A Clin Lung Cancer; 2024 Nov; 25(7):624-633.e2. PubMed ID: 39183094 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report. Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507 [TBL] [Abstract][Full Text] [Related]
14. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis. Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388 [TBL] [Abstract][Full Text] [Related]
15. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801 [No Abstract] [Full Text] [Related]
16. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer. Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L Front Immunol; 2022; 13():918787. PubMed ID: 35795657 [TBL] [Abstract][Full Text] [Related]
17. Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. Jung J; Kim HY; Kim DG; Park SY; Ko AR; Han JY; Kim HT; Lee JS; Lee Y Cancer Res Treat; 2021 Jan; 53(1):77-86. PubMed ID: 32777877 [TBL] [Abstract][Full Text] [Related]